Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from ecancermedicalscience

06:48 EDT 29th June 2017 | BioPortfolio

Here are the most relevant search results for "ecancermedicalscience" found in our extensive news archives from over 250 global news sources.

More Information about ecancermedicalscience on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ecancermedicalscience for you to read. Along with our medical data and news we also list ecancermedicalscience Clinical Trials, which are updated daily. BioPortfolio also has a large database of ecancermedicalscience Companies for you to search.

Showing News Articles 1–25 of 4,300+ from ecancermedicalscience

Wednesday 28th June 2017

Antibody appears to re-activate immune system in cancer therapy

Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukaemia patients with a natural resistance to the drug, according to a small, proof-of-concept study by Duke Cancer Institute...

AML: Two distinct patterns of stem cells explain relapse

by ecancer reporter Janet Fricker Researchers have identified two distinct patterns of therapy resistance cells in acute myeloid leukaemia (AML) already present at diagnosis that explain relapse, reported a study in Nature. The Canadian investigators...

BRCA1 and BRCA2 genes and hereditary breast cancers

Dr Garber talks with ecancer at The Umberto Veronesi Milan Breast Cancer Conference about BRCA1 and BRCA2 genes and genetic testing for hereditary breast cancers.  She goes on to discuss the importance for women to consider their paternal heritage...

Researchers visualise early melanoma metastasis and identify new targets for treatment

Early detection is particularly important in cutaneous melanoma, the most aggressive type of skin cancer: with a thickness of little more than one millimetre, the tumour may begin to spread, sending its cells to colonise other organs. When this occurs,...

Stage 4 breast cancer surgery

Prof Cardoso talks to ecancer at The Umberto Veronesi Milan Breast Cancer Conference about the problems faced when facing the decision about whether to perform surgery in patients with stage 4 metastatic breast cancer at presentation.  She goes on to...

The Umberto Veronesi Milan Breast Cancer Conference

Dr Veronesi talks to ecancer at The Umberto Veronesi Milan Breast Cancer Conference about the conference aims to provide caregivers and scientists interested in breast cancer with results of current research and innovations that enhance patient care and...

Tuesday 27th June 2017

Amber warning for the UK’s access to new medicines post Brexit

Independent health economist lays out solution for how the UK could handle pharmaceutical regulation after Brexit

Monday 26th June 2017

Ribociclib receives positive CHMP opinion as first-line treatment for HR /HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

The European Medicines Agency (EMA) has approved ribociclib in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR /HER2-) locally advanced or...

Tiny nanoparticles offer significant potential in detecting/treating disease

Tiny nanoparticles offer significant potential in detecting and treating disease - new review Exosomes - tiny biological nanoparticles which transfer information between cells - offer significant potential in detecting and treating disease, the most...

FDA grants regular approval to dabrafenib and trametinib combination for metastatic non-small cell lung cancer with BRAF V600E mutation

On June 22, 2017, the U.S. Food and Drug Administration granted regular approvals to dabrafenib and trametinib (tafinlar® and mekinist®, Novartis Pharmaceuticals Inc.) administered in combination for patients with metastatic non-small cell lung cancer...

Microscope can scan tumours during surgery and examine cancer biopsies in 3-D

When women undergo lumpectomies to remove breast cancer, doctors try to remove all the cancerous tissue while conserving as much of the healthy breast tissue as possible. But currently there's no reliable way to determine during surgery whether the...

FDA approves rituximab plus hyaluronidase combination for treatment of follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukaemia

On June 22, 2017, the U.S. Food and Drug Administration granted regular approval to the combination of rituximab and hyaluronidase human (rituxan hycela, Genentech Inc.) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and...

Breast cancer screening with mammography plus ultrasonography or MRI

A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer...

Saturday 24th June 2017

RESONATE at 4 years

Dr Atansio speaks with ecancer at EHA 2017 to report on the 4 year review of ibrutinib for CLL in patients who had previously received tyrosine kinase therapy. ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is...

Latest in relapsed and refractory multiple myeloma

Professor Heinz Ludwig (Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria) is joined by Professor Wee Joo Chng (National University Cancer Institute, Singapore) and Professor James Chim (Queen Mary Hospital, University of Hong Kong,...

Front-line combinations in multiple myeloma: Highlights from EHA 2017

Professor Joy Ho (Royal Prince Alfred Hospital, Sydney, Australia) and Professor Je-Jung Lee (Chairman, Korean Multiple Myeloma Working Party) discuss current treatment paradigms in newly diagnosed multiple myeloma (NDMM), recent advances in combination...

Triplet therapy for all comers in the CLL-BAG trial

Dr Cramer speaks with ecancer at EHA 2017 about the results from CLL-BAG, a trial of bendamustine, obinotuzumab and venetoclax for CLL. She describes the patient population in the trial as including relapsed and treatment naïve patients, and outlines...

Delayed infection exposure as a trigger for childhood ALL

Prof Hauer speaks with ecancer at EHA 2017 about results from a mouse model which suggests that infection in childhood following infant development in clean environments may increase the likelihood of developing paediatric leukaemia. She considers how...

Lenalidomide with CD19 antibodies in L-MIND

Dr Maddocks speaks with ecancer at EHA 2017 about results from a single-armed phase II trial of combined immunomodulatory lenalidomide with anti-CD19 antibody MOR208 to treat refractory diffuse large B cell lymphoma (DLBCL). She describes the monotherapy...

Hemcare - multiple myeloma learning programme

Erik Aerts talks with ecancer at EHA 2017 about the need to incorporate all healthcare professionals into nursing care in order to boost patient advocacy. To view and download the learning programme visit the Hemcare website.  Sarah Liptrott also...

Disruption of BAFF-BCR crosstalk in CLL

Dr Danilov speaks with ecancer at EHA 2017 about a possible driver of resistance to B cell receptor kinases through BAFF-mediated upregulation of Bcl-2. BAFF, a ligand for tumour necrosis factor receptors alongside APRIL, induces NFκB expression,...

The role of patient advocates in trial design, participation

Sarah Liptrott spoke to ecancer at EHA 2017 about patient engagement and advocacy, following her role as co-chair of a conference session on bringing patient perspectives into trial design, Paola Kruger talked to ecancer about involving patients in...

Impact of mutational profile at diagnosis for MDS/CML

Dr Montalban-Bravo speaks with ecancer at EHA 2017 about genomic sequencing of over 200 patients at diagnosis, identifying mutational markers which may predict response to hypomethylating agents He describes that mutations in TET family proteins and p53...

Impact of mutational prodile at diagnosis for MDS/CML

Dr Montalban-Bravo speaks with ecancer at EHA 2017 about genomic sequencing of over 200 patients at diagnosis, identifying mutational markers which may predict response to hypomethylating agents He describes that mutations in TET family proteins and p53...

Blood thinners a risk with cancer-associated venous thromboembolism

Dr Lazo-Langner talks with ecancer at EHA 2017 about weighing the risk of bleeding or clotting in cancer patients after a thrombotic event. Looking at data from almost 7000 patients, he identifies a small risk of bleeding among patients linked to a...


Quick Search
Advertisement
 

News Quicklinks